CDC promotes pre-exposure prophylaxis for HIV preventionBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g3384 (Published 19 May 2014) Cite this as: BMJ 2014;348:g3384
- Bob Roehr
- 1Washington DC
The US Centers for Disease Control and Prevention (CDC) has issued guidance for the broad use of pre-exposure prophylaxis for HIV prevention—better known by the shorthand PrEP—which builds on interim guidance issued in 2012.
Truvada is a single pill containing two commonly used HIV drugs, tenofovir and emtricitabine, and it is the only product that currently carries a label indication for PrEP, although studies of other drugs for PrEP are under way. When taken daily it provides greater than 90% protection against HIV infection.
The new guidance recommended PrEP as an option for four groups of people:
Anyone in …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial